ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintTitle ChevronIcon Twitter
Coronavirus

SoftBank conducts 44,000 antibody tests; 0.43% come back positive

Tech conglomerate leads Japan's largest private coronavirus testing initiative

SoftBank Group Chairman and CEO Masayoshi Son said he decided to conduct the tests "to protect employees, families and customers". (Nikkei Montage/Source photo by Reuters) 

TOKYO -- SoftBank Group on Tuesday revealed the results of 44,066 coronavirus antibody tests conducted on its employees and their families as well as more than 500 medical institutions, the largest such campaign by a private Japanese company.

The tests, conducted between May 12 and June 8, found 191 positive cases, a positive rate of 0.43%.

Of the 38,216 people tested who are linked to the Japanese technology group, 86 were found to have coronavirus antibodies -- a sign of past contact with the virus. So did 105 out of the 5,850 medical workers tested.

In announcing the results in a live-streaming event, Chairman and CEO Masayoshi Son said he decided to conduct the tests "to protect employees, families and customers."

He initially considered polymerase chain reaction tests, which test for the presence of the virus, but settled on antibody tests because they can be done "relatively safely, widely and quickly." The tests at medical institutions were provided at their request.

Son said he feared a large number of infections among workers at the group's mobile phone shops, but was "surprised" that only eight out of 19,075 store staff members tested positive. The figure was lower than 17 out of 10,832 cases that tested positive at offices, even though more than 90% of employees at its Tokyo headquarters worked from home.

He said testing is key to understanding the spread of the virus and take measures to prevent a second wave of infections while opening up the economy. "There is no harm in taking too much tests," he said.

SoftBank's testing initiative could stir debate over the role that the private sector can play in understanding the pandemic. Norio Ohmagari, an infectious disease expert who participated in the event along with Son, said there were "astonishing data" in the results, such as the relatively low rate of positive cases among dentists.

Other companies are following suit as a way to ensure safety for employees and customers as they resume business. Rizap Group, a Tokyo-based operator of high-end fitness gyms, has offered free antibody tests on its 6,500 employees and trainers, as well as gym members.

SoftBank used testing kits from two Chinese manufacturers: Innovita and Orient Gene.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends October 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more